# TGTX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TGTX) · [Earnings tab](https://www.lopjlb.com/stock/TGTX?tab=earnings)

Updated: 2026-08-03T06:33:42

Quarters analyzed: 8

## Cross-quarter narrative

Across the earnings calls, TGTX demonstrated strong and broadening demand for BRIUMVI, with accelerating academic center adoption and record new patient enrollments. The company raised its FY guidance multiple times, driven by commercial execution and pipeline advancements. Notable milestones include the US commercial launch of BRIUMVI, initiation of the subcutaneous BRIUMVI Phase 1 and Phase 3 trials, and the start of the azer-cel CAR-T program. Despite competitive pressure and gross-to-net variability, the company maintained a strong cash position and invested in manufacturing capacity, clinical pipeline expansion, and commercial launch. The narrative evolved to highlight the company's focus on BRIUMVI expansion, pipeline development, and share repurchases, while addressing concerns around competitive dynamics, payer pressure, and clinical execution risk.

## Latest CallCard · Q1

TG Therapeutics Q1 2026: $195M US BRIUMVI revenue, raised FY guidance to $885-900M US; 25k+ patients globally; ENHANCE Phase III data imminent; subcu Phase III enrolled, 2028 launch target; $100M share buyback.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks highlight record revenue, rais

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** TG Therapeutics Q1 2026: $195M US BRIUMVI revenue, raised FY guidance to $885-900M US; 25k+ patients globally; ENHANCE Phase III data imminent; subcu Phase III enrolled, 2028 launch target; $100M share buyback.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks highlight record revenue, rais
- **2025 Q4:** TG Therapeutics reported strong 2025 growth driven by BRIUMVI, reaffirmed 2026 revenue guidance, and highlighted upcoming ENHANCE and subcutaneous data as key catalysts.
- **2025 Q3:** TG Therapeutics reports strong Q3 with $153M BRIUMVI sales, raises 2025 guidance to ~$585M, advances subcu and ENHANCE trials, completes $100M buyback, authorizes another $100M.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights strong commercial execution, raised guidance, pipeline pro
- **2025 Q2:** TGTX Q2'25: BRIUMVI sales $139M (+91% YoY), FY guidance raised to $575M; subcu Phase III enrollment starting, azer-cel CAR-T first patient dosed; gross-to-net ~70% on hospital mix. Cash $279M. No Q3 guidance. TV campaign launched.
- **2025 Q1:** TG Therapeutics reports strong Q1 2025 with BRIUMVI US net sales of $119.7M (+137% YoY), raises full-year guidance to $560M, advances simplified IV dosing and subcutaneous programs, and initiates Phase 1 for azer-cel in progressive MS.
- **2024 Q4:** TGTX Q4: $310M FY24 revenue beats guidance; 2025 guidance $525M; subcutaneous BRIUMVI pivotal mid-2025; azer-cel Phase 1 enrolling; patents to 2042.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize strong 2024 outperformance ($310M revenue vs guidance), positive clinical data (5-
- **2024 Q3:** TGTX Q3 BRIUMVI sales $83.3M (+15% QoQ), raised FY guidance to $300-305M; positive ECTRIMS data, subcu update early 2025, azer-cel Phase 1 starting, added second manufacturer.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights strong sales growth, raised guidance, positive clinical data
- **2024 Q2:** TGTX Q2 BRIUMVI sales $72.6M beat $65M target; raised FY guidance to $290-300M; first cash-flow positive quarter; $250M credit facility funds $100M buyback; subcu BRIUMVI Ph1 started

## Theme arcs

- **Demand and Commercial Execution** (improving): Strong and broadening demand with accelerating academic center adoption
- **Pipeline Advancements** (improving): Initiation of subcutaneous BRIUMVI Phase 1 and Phase 3 trials, and azer-cel CAR-T program
- **Competitive Dynamics** (deteriorating): Ocrevus Zunovo launch and other anti-CD20 therapies could pressure market share gains
- **Gross-to-Net Variability** (stable): Gross-to-net ~70% in Q2 due to hospital segment mix
- **Cash Position and Investments** (improving): Strong cash position and investments in manufacturing capacity, clinical pipeline expansion, and commercial launch
- **Clinical Execution Risk** (stable): Subcutaneous pivotal trial, MG Phase 1, and azer-cel Phase 1 carry clinical and regulatory risk

## Fear persistence

- **Competitive Dynamics** [recurring]: Ocrevus Zunovo launch and other anti-CD20 therapies could pressure market share gains
- **Gross-to-Net Variability** [recurring]: Gross-to-net ~70% in Q2 due to hospital segment mix
- **Clinical Execution Risk** [recurring]: Subcutaneous pivotal trial, MG Phase 1, and azer-cel Phase 1 carry clinical and regulatory risk
- **Payer Pressure** [new]: Potential payer push for lower-cost at-home therapies could accelerate shift from IV to subcu
- **Manufacturing Concentration** [new]: Single-source manufacturing in South Korea creates supply chain vulnerability

## Guidance path

2024 Q2:raised → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:raised → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TGTX`